Mitomycin C in large infrequent doses in breast cancer

✍ Scribed by Wise, Gregory R. ;Kuhn, Irvin N. ;Godfrey, Thomas E.

• Publisher: John Wiley and Sons
• Year: 1976
• Tongue: English
• Weight: 415 KB
• Volume: 2
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950020106

✦ Synopsis

Abstract

Seventy‐one women with far‐advanced breast cancer resistant to standard chemotherapeutic agents were administered mitomycin C using an intermittent high dose schedule. One group consisted of 54 patients with measurable metastatic tumor; a second group consisted of 18 patients with nonmeasurable osseous metastases. Objective response rate in group 1 was 26% for an average duration of 2 1/2 months. Subjective response rate in group 2 was 44% for an average duration of 3 months. Response and toxicity data were similar to those of studies employing the less convenient protracted low‐dose schedule. Prior treatment with other alkylating agents did not adversely affect response. Further investigation into the role of mitomycin in combination chemotherapy programs is recommended.